-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 6, the National Medical Security Bureau announced the list of drugs that passed the preliminary form review in the adjustment of the national basic medical insurance, work injury insurance and maternity insurance drug catalogue in 2022, and 344 drugs passed the preliminary form review
.
.
The adjustment of the national medical insurance information platform received a
total of 537 enterprise declarations, involving 490 drugs.
After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.
Compared with last year, the number of drugs declared and passed the preliminary form examination has increased
to a certain extent.
Enterprise enterprisetotal of 537 enterprise declarations, involving 490 drugs.
After review, 344 drugs passed the preliminary form examination, and the proportion of passing was 70%.
Compared with last year, the number of drugs declared and passed the preliminary form examination has increased
to a certain extent.
According to the "2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue Adjustment Work Plan", the adjustment of the medical insurance drug catalogue is divided into enterprise declaration, formal review, expert review, negotiation and bidding and other links
.
The preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug list in that year and the completeness of drug information.
Passing the formal examination indicates that the drug is eligible for the next step of expert review
.
.
The preliminary formal review is a preliminary review
of whether the declared drugs meet the conditions for the adjustment of the national medical insurance drug list in that year and the completeness of drug information.
Passing the formal examination indicates that the drug is eligible for the next step of expert review
.
Since its establishment in 2018, the National Medical Insurance Bureau has adjusted the medical insurance drug list for four consecutive years, accumulatively including 507 new drugs and good drugs, transferring 391 drugs with inaccurate efficacy, and increasing the current version of the medical insurance directory to 2860 Western medicines and proprietary Chinese medicines
.
The shortcomings of oncology drugs, chronic diseases, rare diseases and children's drugs have been gradually filled, the structure and efficacy level of drugs in the medical insurance catalogue have been greatly optimized, and the drug guarantee in most treatment areas has been synchronized with the international community, and the protection capacity has been significantly improved
.
Among them, 250 drugs have been included in medical insurance through price negotiations, many "sky-high drugs" have negotiated "civilian prices", and most drugs have obtained the lowest prices in the world, with an average price reduction of more than 50%.
Drugs for children with tumor tumors in children.
The shortcomings of oncology drugs, chronic diseases, rare diseases and children's drugs have been gradually filled, the structure and efficacy level of drugs in the medical insurance catalogue have been greatly optimized, and the drug guarantee in most treatment areas has been synchronized with the international community, and the protection capacity has been significantly improved
.
Among them, 250 drugs have been included in medical insurance through price negotiations, many "sky-high drugs" have negotiated "civilian prices", and most drugs have obtained the lowest prices in the world, with an average price reduction of more than 50%.
In order to do a good job in the prevention and control of the new crown epidemic, the National Medical Insurance Bureau previously issued regulations to temporarily include relevant drugs in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia" into the scope of medical insurance payment, providing strong support
for epidemic prevention and control.
Then, if the drugs temporarily included in the scope of payment want to be officially included in the list, they also need to go through the process
of adjusting the drug list.
Among the list released this time is the first domestic new crown oral drug azilvidine tablets
.
for epidemic prevention and control.
Then, if the drugs temporarily included in the scope of payment want to be officially included in the list, they also need to go through the process
of adjusting the drug list.
Among the list released this time is the first domestic new crown oral drug azilvidine tablets
.
Since the outbreak of the new crown epidemic, the National Medical Insurance Bureau has attached great importance to the treatment of new crown pneumonia drugs, and the previous catalogue adjustment work has included a number of new crown treatment drugs into the medical insurance drug catalog
.
In order to better protect the needs of diagnosis and treatment, the National Medical Insurance Bureau also stipulates that all drugs included in the diagnosis and treatment plan of new crown pneumonia can be temporarily included in the scope of
medical insurance payment.
In August this year, the National Health Commission issued a notice to include Azifdine tablets in the diagnosis and treatment plan for the new coronavirus pneumonia, so the medical insurance fund can pay
for the use of the drug by insured patients in accordance with the regulations.
In this declaration, the first domestic new crown oral drug azifriculture tablets have passed the preliminary form review
.
The National Medical Insurance Bureau said that it will carry out follow-up work in accordance with the procedures and strive to be officially included in the medical insurance directory
at a reasonable price.
Healthy and healthy .
In order to better protect the needs of diagnosis and treatment, the National Medical Insurance Bureau also stipulates that all drugs included in the diagnosis and treatment plan of new crown pneumonia can be temporarily included in the scope of
medical insurance payment.
In August this year, the National Health Commission issued a notice to include Azifdine tablets in the diagnosis and treatment plan for the new coronavirus pneumonia, so the medical insurance fund can pay
for the use of the drug by insured patients in accordance with the regulations.
In this declaration, the first domestic new crown oral drug azifriculture tablets have passed the preliminary form review
.
The National Medical Insurance Bureau said that it will carry out follow-up work in accordance with the procedures and strive to be officially included in the medical insurance directory
at a reasonable price.
